Eight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 billion Acceleron acquisition. In the phase 3 ZENITH study, Merck’s ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR ...

2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR ...

FDA researchers have found new evidence of a molecular link between Merck’s former blockbuster asthma drug montelukast—which is now marketed by spinoff Organon under the brand name Singulair—with ...

Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from Chinese news outlets and confirmation from industry sources in the country.

Merck's revenue was about $16.66 billion for the three months ended September 30, 2024, up 4.39% year over year and beating both my expectations and Wall Streets', thanks to stronger sales of ...

Mark Kleinman, Sky News’ City editor, posted on X, the service formerly known as Twitter: “Revealed: Merck (MRK), the US-listed pharma group, is the latest industry giant to be linked to a ...

Merck said a new formulation of the best-selling drug, Keytruda, appears to deliver similar blood levels of the medicine when it is given as a shot as when it is given intravenously. For Merck ...

Nov 19 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of ...

RAHWAY, N.J., November 19, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK ...

I expect 10 companies to announce their annual increases in the second half of November, including modest increases from Merck and a 10%+ increase from Raymond James Financial. Hormel Foods is ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments. The deal with ...